Characteristics and treatment pathways of COPD patients initiating single-inhaler dual or triple therapy in England

Conclusions: New users of FF/UMEC/VI were more breathless, had worse lung function and more prior exacerbations at therapy initiation than new users of single-inhaler dual therapies in England. ICS/LABA and LAMA/LABA single-inhaler new users mostly stepped up from ICS and LAMA monotherapy, respectively, or were initial maintenance therapy users, whilst most FF/UMEC/VI new users switched from prior MITT use.Funding: GSK 2145933

Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Noorduyn, S. G., Wood, R. P., Rothnie, K. J., Rai, K. K., Seif, M., Massey, L., Compton, C., Ismaila, A. S. Tags: Airway pharmacology and treatment Source Type: research